Document is current
Any future updates will be listed below
-
Authors
Lehrke, Michael https://orcid.org/0000-0003-2484-8068
Vogt, Anja
Schettler, Volker https://orcid.org/0000-0002-6193-6377
Girndt, Matthias https://orcid.org/0000-0003-2823-0847
Fraass, Uwe https://orcid.org/0000-0001-6588-0318
Tabbert-Zitzler, Anja
Bridges, Ian https://orcid.org/0000-0002-3317-3528
Dhalwani, Nafeesa N. https://orcid.org/0000-0001-7368-3306
Ray, Kausik K. https://orcid.org/0000-0003-0508-0954
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02770131 at ClinicalTrials.govDocuments that mention this clinical trial
Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study
https://doi.org/10.1007/s12325-023-02757-x
- License Information
-
More Information
Article History
Received: 27 October 2023
Accepted: 29 November 2023
First Online: 30 January 2024
Declarations
:
: Michael Lehrke received grants and personal fees from Boehringer Ingelheim, MSD, Novo Nordisk and personal fees from Amgen, Sanofi, AstraZeneca, Bayer, Lilly, Daiichi Sankyo, Novarits. Volker Schettler declares to have received speaker’s fees, travel support and/or study grants from Amgen GmbH, Akcea GmbH, B.Braun Avitum AG, Daiichi Sankyo Deutschland GmbH, Fresenius Medical Care AG & Co. KGaA, KWHC Health Consulting GmbH, Novartis Pharma GmbH, Novo Nordisk GmbH, Sanofi-Aventis GmbH, Vifor Deutschland GmbH. Matthias Girndt declares speaker’s and advisory fees from Amgen GmbH, Astellas GmbH, Bayer Vital GmbH, Daiichi Sankyo GmbH, Hexal AG, Novartis GmbH, Novo Nordisk GmbH, Pfizer GmbH, Sanofi GmbH, Vifor Fresenius GmbH. Anja Vogt declares speaker’s and advisory fees from Aegerion, Amgen GmbH, Daiichi Sankyo GmbH, MSD GmbH, Novartis GmbH, Sanofi GmbH. Kausik K. Ray reports grants/personal fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cargene, Daiichi Sankyo, Esperion, Kowa, Lilly, New Amsterdam Pharma, Novartis, Pfizer, Sanofi-Regeneron, Silence Therapeutics and Scribe Therapeutics. Ian Bridges is an employee of Amgen Ltd and stockholder of Amgen; Uwe Fraass and Anja Tabbert-Zitzler are employees of Amgen GmbH and stockholders of Amgen; Nafeesa N. Dhalwani is an employee of Amgen Inc. and stockholder of Amgen.
: This study was conducted according to the Declaration of Helsinki and the guidelines of the International Council for Harmonization. The study was registered in ClinicalTrials.gov (Identifier NCT02770131). The study protocol and the protocol amendments were approved by the institutional ethics committees of each participating study center (Supplemental Table S1); the ethics committee of the Bavarian state medical association acted as the lead ethics committee for the German sub-study of HEYMANS (study reference number 16030). All patients or their legally acceptable representatives provided written informed consent before participation in this study.
